Thrombosis research最新文献

{"title":"Management strategies and clinical outcomes of venous thromboembolism in patients with antiphospholipid syndrome in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2","authors":"Takahiro Kuno , Norimichi Koitabashi , Yugo Yamashita , Takeshi Morimoto , Yoshiaki Ohyama , Noriaki Takama , Masaru Obokata , Ryuki Chatani , Kazuhisa Kaneda , Yuji Nishimoto , Nobutaka Ikeda , Yohei Kobayashi , Satoshi Ikeda , Kitae Kim , Moriaki Inoko , Toru Takase , Shuhei Tsuji , Maki Oi , Takuma Takada , Kazunori Otsui , Takeshi Kimura","doi":"10.1016/j.thromres.2025.109311","DOIUrl":"10.1016/j.thromres.2025.109311","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109311"},"PeriodicalIF":3.7,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143696028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a clinically relevant rat model of chronic thromboembolic pulmonary hypertension by combining splenectomy with pulmonary thromboembolism","authors":"Haobing Zhang ,&nbsp;Xiaoxuan Lu ,&nbsp;Zhuangjie Guo ,&nbsp;Xuehan Jiang ,&nbsp;Wensi Zhang ,&nbsp;Shuang Wang ,&nbsp;Qiwei Liu ,&nbsp;Xiaotong Dong ,&nbsp;Yishan Li ,&nbsp;Lina Guo ,&nbsp;Yu Zhang ,&nbsp;Jixiang Liu ,&nbsp;Zhu Zhang ,&nbsp;Wanmu Xie ,&nbsp;Wanlu Song ,&nbsp;Hong Zhang ,&nbsp;Zhenguo Zhai ,&nbsp;Peiran Yang","doi":"10.1016/j.thromres.2025.109310","DOIUrl":"10.1016/j.thromres.2025.109310","url":null,"abstract":"<div><h3>Background</h3><div>Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe condition resulting from unresolved thrombi in the pulmonary arteries, leading to increased pulmonary vascular resistance and right heart failure. Currently, the scarcity of clinically relevant animal models of CTEPH significantly hampers mechanistic studies and drug development.</div></div><div><h3>Methods</h3><div>This study aimed to establish a rat model of CTEPH by combining splenectomy with thrombus injection, simulating key clinical risk factors associated with the disease. Rats underwent splenectomy and subsequent intravenous administration of thrombi, followed by hemodynamic and histological measurements as well as lung tissue RNA sequencing.</div></div><div><h3>Results</h3><div>Splenectomized rats exhibited significant increases in platelets and delayed thrombolysis. Five weeks after splenectomy and thrombus injection, the rats exhibited thrombus retention in large pulmonary arteries, increased right ventricular systolic pressure, and pulmonary vascular remodeling, which were characteristic of CTEPH. Transcriptomic analysis revealed increased expression of inflammatory cytokines <em>Ccl2</em> and <em>Ccl3</em>, as well as the B cell marker <em>Cd79a</em>, which was confirmed as an increase in CD79A⁺ B cells in the lung tissue.</div></div><div><h3>Conclusions</h3><div>Overall, this novel approach of combining splenectomy with thrombus injection provides a clinically relevant model for studying CTEPH pathophysiology and evaluating potential therapeutic interventions.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109310"},"PeriodicalIF":3.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolomics profiling in venous thromboembolism and its chronic sequelae - A systematic review","authors":"Zahra Amirsardari ,&nbsp;Asal Khalili ,&nbsp;Mohammadhasan Sharafi ,&nbsp;Reza Mehrizi ,&nbsp;Shana Ahadi ,&nbsp;Amirhossein Roshanshad ,&nbsp;Mahshid Malakootian","doi":"10.1016/j.thromres.2025.109309","DOIUrl":"10.1016/j.thromres.2025.109309","url":null,"abstract":"<div><h3>Background</h3><div>High-throughput metabolomics studies have advanced the identification of novel biomarkers and enhanced the understanding of the pathogenesis of venous thrombosis. This systematic review aims to summarize metabolomics research conducted on venous thromboembolism (VTE), as well as its chronic sequelae, including chronic thromboembolic pulmonary hypertension (CTEPH) and post-thrombotic syndrome (PTS), encompassing both pre-clinical and clinical investigations.</div></div><div><h3>Methods</h3><div>A systematic search using relevant keywords related to metabolomics profiling and venous thromboembolism was conducted across four databases (PubMed, Embase, Scopus, and Web of Science). Quality assessment for animal studies was performed using SYRCLE, and for human studies, QUADOMICS was used. The study protocol is registered in PROSPERO under registry code CRD42024529490.</div></div><div><h3>Results</h3><div>Multiple metabolic disturbances were identified in various venous thrombotic conditions, including dysregulations in cellular respiration and the metabolism of carbohydrates, amino acids, lipids, and nucleic acids. Notably, altered levels of serum amino acids and their derivatives were frequently reported in patients with venous thrombosis, though findings regarding specific amino acids such as alanine, arginine, and tryptophan were inconsistent. Additionally, disruptions in tricarboxylic acid (TCA) cycle metabolites were commonly observed. Pathway enrichment analysis revealed significant involvement of several metabolic pathways, including valine, leucine, and isoleucine biosynthesis; alanine and aspartate metabolism; <span>d</span>-glutamine and D-glutamate metabolism; and arginine metabolism.</div></div><div><h3>Conclusions</h3><div>This systematic review offers a comprehensive overview of metabolomics research in venous thromboembolism and its chronic sequelae, identifying the most affected metabolic pathways associated with disease progression.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109309"},"PeriodicalIF":3.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres","authors":"Susanna Ranta ,&nbsp;Ester Zapotocka ,&nbsp;Nadine G. Andersson ,&nbsp;Kathelijn Fischer ,&nbsp;Gili Kenet ,&nbsp;Marloes de Kovel ,&nbsp;Christoph Königs ,&nbsp;Veerle Labarque ,&nbsp;Christoph Male ,&nbsp;Martin Olivieri ,&nbsp;Jayashree Motwani","doi":"10.1016/j.thromres.2025.109307","DOIUrl":"10.1016/j.thromres.2025.109307","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109307"},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding primary antiphospholipid syndrome: Analyzing antiphospholipid antibody profile and titers correlation to hematological activity and development of predictive models","authors":"Amaya Llorente-Chávez ,&nbsp;Rodrigo Figueroa-Méndez ,&nbsp;Alejandro Quintero-Villegas ,&nbsp;Gabriela Hernández-Molina ,&nbsp;Theodoros Zanos ,&nbsp;Alfonso Orozco-Collazo","doi":"10.1016/j.thromres.2025.109308","DOIUrl":"10.1016/j.thromres.2025.109308","url":null,"abstract":"<div><div><ul><dt>aCL: anticardiolipin.</dt><dt>ACR: American College of Rheumatology.</dt><dt>AIHA: autoimmune hemolytic anemia.</dt><dt>anti-β2GPI: anti-β2 glycoprotein-I.</dt><dt>aPLA: antiphospholipid antibodies.</dt><dt>APS: antiphospholipid syndrome.</dt><dt>aPS/PT: antiphosphatidyl serine/prothrombin.</dt><dt>ATE: arterial thrombotic event.</dt><dt>ATE + VTE: arterial and venous thrombotic event.</dt><dt>dL: deciliter.</dt><dt>EULAR: European Alliance of Assocciations for Rheumatology.</dt><dt>g: gram.</dt><dt>GBM: Gradient Boosting Machine.</dt><dt>IQR: interquartile range.</dt><dt>KNN: K-nearest neighbors'.</dt><dt>LA: lupus anticoagulant.</dt><dt>L: liter.</dt><dt>mL: mililiter.</dt><dt>MPV: mean platelet volume.</dt><dt>OR: odds ratio.</dt><dt>pAPS: primary antiphospholipid syndrome.</dt><dt>ROC-AUC: Receiver Operating Characteristic Area Under the Curve.</dt><dt>SHAP: SHapley Additive exPlanations.</dt><dt>SVM: Support Vector Machine.</dt><dt>U: units.</dt><dt>UGPL: immunoglobulins isotype.</dt><dt>VTE: venous thrombotic event.</dt><dt>XGBoost: Extreme Gradient Boosting Machine.</dt></ul></div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109308"},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of My Precise Dose and WAPPS-Hemo as dosing tools for optimizing prophylaxis in children with hemophilia A treated with BAY 81-8973","authors":"Yaohan Zhou ,&nbsp;Di Ai ,&nbsp;Xiaoling Cheng ,&nbsp;Gang Li ,&nbsp;Yingzi Zhen ,&nbsp;Xinyi Wu ,&nbsp;Guoqing Liu ,&nbsp;Wanru Yao ,&nbsp;Zekun Li ,&nbsp;Zhenping Chen ,&nbsp;Runhui Wu","doi":"10.1016/j.thromres.2025.109305","DOIUrl":"10.1016/j.thromres.2025.109305","url":null,"abstract":"<div><h3>Background</h3><div>Dense sampling served as the foundation for the conventional calculation of pharmacokinetic (PK) parameters. Individual PK can now be estimated via sparse sampling thanks to the development of Bayesian population PK (popPK). Both My Precise Dose (MPD) and the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) use the popPK model of BAY 81-8973 to forecast personalized dosage.</div></div><div><h3>Objective</h3><div>To compare the PK profiles and dosage estimates provided by WAPPS-Hemo and MPD for prophylaxis in children with hemophilia A treated with BAY 81-8973.</div></div><div><h3>Methods</h3><div>Thirty-eight pediatric patients with severe hemophilia A were enrolled. After a 72-h washout period, each patient received a 50 IU/kg infusion of BAY 81-8973. PK parameters were calculated at three time points: pre-dose, 3 h, and 24 h after infusion. Dosing regimens to maintain FVIII trough levels at 1 and 3 IU/dL were determined using the WAPPS-Hemo and MPD models, respectively.</div></div><div><h3>Results</h3><div>Among the 38 pediatric patients with a median age of 5.7 years (range: 2.8–11.2 years), the MPD exhibited superior values for the half-life (T_1/2) and area under the curve (AUC) in comparison to the WAPPS-Hemo, while demonstrating reduced clearance (CL) and steady-state volume of distribution (VSS). WAPPS-Hemo made more mistakes when predicting FVIII activity at 48 h (28.84 %) and 72 h (50.19 %), but only 12.45 % and 47.44 % of the time when predicting by MPD. Statistical analysis indicated a significant difference between the two techniques regarding individual dosage at both 1 IU/dL and 3 IU/dL. [(1 IU/dL: WAPPS-Hemo 12.1 (9.3, 17.1) vs. MPD 7.3 (5.5, 9.9), <em>P</em> &lt; 0.001; 3 IU/dL: WAPPS-Hemo 36.3 (27.8, 51.3) vs. MPD 21.9 (16.4, 30.0), P &lt; 0.001).].</div></div><div><h3>Conclusions</h3><div>The pediatric popPK model such as MPD tailored for conditions can more precisely represent the PK characteristics and metabolic conditions of Chinese children in real-world settings, highlighting its potential utility in the clinical care of hemophilia patients.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109305"},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143682771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FVIII half-life products: A real-world experience","authors":"Ezio Zanon ,&nbsp;Annamaria Porreca ,&nbsp;Angela Napolitano ,&nbsp;Chiara Simion ,&nbsp;Paolo Simioni","doi":"10.1016/j.thromres.2025.109306","DOIUrl":"10.1016/j.thromres.2025.109306","url":null,"abstract":"<div><h3>Background</h3><div>Haemophilia A is a genetic coagulation disorder requiring prophylactic Factor VIII (FVIII) treatment to prevent joint damage and enhance quality of life. The introduction of extended half-life (EHL) FVIII products represents a major advancement, addressing patient needs for reduced infusion frequency, improved efficacy, and enhanced safety.</div></div><div><h3>Methods</h3><div>This single-centre observational study examined the real-world use of FVIII products among 124 male patients treated at the Haemophilia Centre of Padua from January 2018 to December 2023. Data on patient characteristics, treatment regimens, and pharmacokinetic profiles were analyzed.</div></div><div><h3>Results</h3><div>Among the FVIII products used, Advate®, Elocta®, and Jivi® showed median half-lives of 11.25 [10.75–12.25], 16.50 [13.75–17.75], and 15.38 [13.38–18.63] hours, respectively. Esperoct® exhibited the longest half-life at 19.75 [16.00–24.50] hours, enabling reduced infusion frequency. EHL products showed significantly lower weekly infusion rates compared to standard half-life (SHL) products (1.4 [1.0–2.0] vs. 2.0 [2.0–3.0], <em>p</em> &lt; 0.001), with comparable bleeding control among the different FVIII-EHL.</div></div><div><h3>Conclusions</h3><div>EHL FVIII products offer significant clinical benefits, reducing the burden of frequent infusions and improving adherence while maintaining effective bleeding control. Despite these advancements, comprehensive evaluations of cost, safety, and long-term outcomes are essential to optimize their integration into haemophilia care.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109306"},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of clinical manifestations and molecular pathogenesis of six patients with hereditary blood coagulation factor VII deficiency","authors":"Yu Song,&nbsp;Yao Lu,&nbsp;Linzi Miao,&nbsp;Yuanyuan Li,&nbsp;Anna Jiang,&nbsp;Chenxue Qu","doi":"10.1016/j.thromres.2025.109304","DOIUrl":"10.1016/j.thromres.2025.109304","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary blood coagulation factor VII (FVII) deficiency is a rare hemorrhagic disorder inherited in an autosomal recessive pattern, involving variants in the gene encoding FVII (<em>F7</em>). The sites and types of <em>F7</em> mutations could influence the coagulation activity of plasma FVII (FVII: C) and the severity of hemorrhage symptoms. However, the specific molecular mechanisms of FVII deficiency are still unclear.</div></div><div><h3>Objective</h3><div>To analyze clinical manifestations and coagulation functions of six patients of hereditary FVII deficiency and explore specific molecular mechanisms of the disease.</div></div><div><h3>Methods</h3><div>We detected coagulation functions including prothrombin time (PT), activated partial thromboplastin time (APTT), PT mixing study and FVII: C. Then genomic DNA of six patients was sequenced through whole exome sequencing (WES). Furthermore, we analyzed and predicted conservatism of the amino acid mutation sites, pathogenicity of mutations and structures of the mutated proteins by bioinformatics tools.</div></div><div><h3>Results</h3><div>Five patients presented as asymptomatic while only one female experiencing intermittent epistaxis. PT was prolonged and corrected to reference range, and FVII: C was significantly decreased in all patients. Nine mutations were identified, of which three (c.1261delA, c.362G&gt;A and c.227A&gt;G) were reported for the first time. The mutation (c.1261delA) triggered nonsense-mediated mRNA decay (NMD) mechanism, resulting in degradation of abnormal mRNA. The mutation (c.362G&gt;A) might disrupt formation of disulfide bond, affecting normal folding of functional domain. Moreover, protein modeling revealed the formation of a new hydrogen bond. Using ProtScale to analyze the hydrophobicity of the mutation (c.227A&gt;G), it was clear that hydrophobicity of amino acids was enhanced.</div></div><div><h3>Conclusion</h3><div>We have identified three novel mutations and performed analysis that might illuminate the molecular pathogenesis of hereditary coagulation FVII deficiency.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109304"},"PeriodicalIF":3.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Who are we bridging? Description of warfarin patients receiving injectable bridging therapy","authors":"Sara R. Vazquez ,&nbsp;Connor Jensen ,&nbsp;Aaron S. Wilson ,&nbsp;Daniel M. Witt","doi":"10.1016/j.thromres.2025.109303","DOIUrl":"10.1016/j.thromres.2025.109303","url":null,"abstract":"<div><h3>Purpose</h3><div>The evidence guiding the decision to provide injectable anticoagulant bridging therapy during periods of subtherapeutic warfarin anticoagulation is sparse. This study aims to identify the types of patients currently bridged within an academic medical center's Thrombosis Service, to highlight patient populations for future study of bridging outcomes.</div></div><div><h3>Methods</h3><div>This descriptive cohort study included patients taking warfarin managed by University of Utah Health Thrombosis Service who received outpatient enoxaparin bridging between January 1 and December 31, 2022. Anticoagulation indication, reason for bridging, and type of procedure were validated via manual chart review.</div></div><div><h3>Results</h3><div>During the one-year study period, 181 unique patients (9.4 % of the service's total warfarin population) experienced 244 bridging episodes, mostlyin the periprocedural setting (67.6 %) for gastrointestinal-type procedures (39.4 %). The most common anticoagulation indications in all bridged patients were antiphospholipid syndrome (APS) (23.2 %), venous thromboembolism (VTE) (21.5 %), or a mechanical mitral valve plus another indication (13.3 %). Most bridging episodes for VTE occurred &gt;3 months from the acute event, with the rationale for bridging including breakthrough VTE (31 %) or APS (23 %). Just over one-half of bridged patients fit the guideline-recommended criteria for high thrombotic risk, and just over one-third were low-moderate thrombotic risk.</div></div><div><h3>Conclusions</h3><div>In this one-year outpatient study, warfarin patients received enoxaparin bridging most commonly due to a gastrointestinal procedural interruption in the setting of APS, VTE with a prior breakthrough thrombotic event, or mechanical mitral valve. Just over one-third of bridged patients were guideline-classified as low-moderate thrombotic risk, indicating these populations may warrant further investigation or bridging de-escalation.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109303"},"PeriodicalIF":3.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: A systematic review and meta-analysis","authors":"Wenchi Li ,&nbsp;Shuyue Sheng ,&nbsp;Feng Zhu","doi":"10.1016/j.thromres.2025.109302","DOIUrl":"10.1016/j.thromres.2025.109302","url":null,"abstract":"<div><h3>Objective</h3><div>Multiple organ damage is a hallmark of the highly lethal condition known as disseminated intravascular coagulation (DIC). The efficacy and safety of recombinant human soluble thrombomodulin (rhTM) and antithrombin (AT) in DIC is still debatable. Therefore, we used a fixed-effects model to conduct a comprehensive evaluation and meta-analysis to examine the safety and efficacy of AT or rhTM administration for treating DIC.</div></div><div><h3>Methods</h3><div>Up until September 2024, the databases of the Cochrane Library, Embase, Web of Science, PubMed, and CNKI were searched for pertinent papers that satisfied the inclusion requirements. Following the researchers' review of the literature, data extraction, and quality assessment, RevMan 5.4 software was used to conduct meta-analysis.</div></div><div><h3>Results</h3><div>The AT group included two randomized controlled trials with 95 patients, 47 in the test and 48 in the control groups. The test group's DIC resolution rate was higher than the control group's (OR = 5.21 [2.10, 12.90], P = 0.0004), while the 28-day mortality and bleeding-related adverse events did not differ significantly (OR = 0.45 [0.16, 1.31], P = 0.14; OR = 1.02 [0.22, 4.74], P = 0.98). Of the 1105 patients in the rhTM group, 554 were in the trial group and 551 were in the control group across four randomized controlled trials. The trial group showed a greater rate of DIC resolution than the control group (OR = 1.76 [1.34, 2.30], P &lt; 0.0001), although there was no significant difference in the 28-day mortality rate or bleeding-related adverse events. (OR = 0.79 [0.59, 1.05], P = 0.11; OR = 1.08 [0.63, 1.86], P = 0.78).</div></div><div><h3>Conclusion</h3><div>Both AT and rhTM therapy improved the rate of symptomatic relief in patients with DIC without increasing the risk of bleeding, but there was no benefit in terms of their mortality.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"249 ","pages":"Article 109302"},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}